KR102127282B1 - Composition for Anti-inflammatory Comprising Biorenovation Extract of Prunus yedoensis Matsum - Google Patents
Composition for Anti-inflammatory Comprising Biorenovation Extract of Prunus yedoensis Matsum Download PDFInfo
- Publication number
- KR102127282B1 KR102127282B1 KR1020190121316A KR20190121316A KR102127282B1 KR 102127282 B1 KR102127282 B1 KR 102127282B1 KR 1020190121316 A KR1020190121316 A KR 1020190121316A KR 20190121316 A KR20190121316 A KR 20190121316A KR 102127282 B1 KR102127282 B1 KR 102127282B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- inflammatory
- extract
- bioconversion
- yoshino cherry
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 10
- 235000011442 Prunus x yedoensis Nutrition 0.000 title claims description 38
- 241000220307 Prunus yedoensis Species 0.000 title claims description 38
- 238000000034 method Methods 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 108090000695 Cytokines Proteins 0.000 claims abstract description 9
- 102000004127 Cytokines Human genes 0.000 claims abstract description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 7
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- 230000004054 inflammatory process Effects 0.000 claims abstract description 6
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 4
- 150000003180 prostaglandins Chemical class 0.000 claims abstract description 4
- 238000009472 formulation Methods 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 241000193744 Bacillus amyloliquefaciens Species 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 claims 1
- 235000003840 Amygdalus nana Nutrition 0.000 abstract 3
- 235000011432 Prunus Nutrition 0.000 abstract 3
- 241000220299 Prunus Species 0.000 abstract 3
- 235000014774 prunus Nutrition 0.000 abstract 3
- 238000000605 extraction Methods 0.000 description 11
- 239000000654 additive Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 229960002986 dinoprostone Drugs 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 240000002791 Brassica napus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 241001290151 Prunus avium subsp. avium Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 1
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- GQZXNSPRSGFJLY-UHFFFAOYSA-N hydroxyphosphanone Chemical group OP=O GQZXNSPRSGFJLY-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- -1 softeners Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 생물전환법을 통해 왕벚나무로부터 추출된 왕벚나무 생물전환 추출물을 유효성분으로 포함하는 항염용 조성물에 관한 것이다. The present invention relates to a composition for anti-inflammatory comprising a Yoshino cherry bio-conversion extract extracted from Yoshino cherry tree through a bioconversion method.
생물전환법(biorenovation)이란 미생물이 가지고 있는 효소적 기능을 이용하여 전구물질로부터 원하는 산물을 생산 또는 제조하는 방법을 말하며, 미생물 발효 또는 효소처리 등의 생물학적 방법을 통해 물질의 구조적 변화를 유도시키는 방법을 통칭한다. 상기 변화로 인하여 유효성분의 함량이 증가하거나 흡수율이 개선되고, 새로운 기능성분이 생성된다는 사실이 새롭게 알려지고 있으며 이러한 기법을 이용한 소재 개발이 전 세계적으로 주목을 받고 있다.Biorenovation (biorenovation) refers to a method of producing or manufacturing a desired product from precursors using enzymatic functions of microorganisms, and inducing structural changes of substances through biological methods such as microbial fermentation or enzymatic treatment. Collectively. It is newly known that the content of the active ingredient is increased or the absorption rate is improved and new functional components are generated due to the above changes, and material development using these techniques has attracted attention worldwide.
이러한 생물전환법은 항생제, 스테로이드를 포함한 의약품 및 의약품 원료물질의 생산뿐만 아니라 아미노산, 비타민 등의 유용 물질의 생산에 널리 이용되고 있다. 선진국의 경우 생물공학 기법으로 인한 제품의 출시로 고부가가치를 목표로 한 제품들이 다수 판매되고 있으며, 이러한 신 바이오 기술 기반 소재는 소비자로부터 안전성이 인정되어 최근에 다양한 생물공학기술을 체계적으로 융합한 다양한 기능성 소재가 등장하고 있다.These bioconversion methods are widely used in the production of useful substances such as amino acids and vitamins, as well as the production of pharmaceutical and pharmaceutical raw materials including antibiotics and steroids. In developed countries, a number of products aimed at high value-added products are sold due to the release of products due to biotechnology, and these new biotechnology-based materials have been recognized by consumers as safety, and various biotechnological technologies have recently been systematically fused. Functional materials are emerging.
이에 본 발명자들은 신규 소재 및 이의 제조방법을 발굴하기 위해 노력한 결과, 생물전환법을 통해 왕벚나무 생물전환 추출물을 생산 및 활용함으로써 본 발명을 완성하였다.As a result, the inventors of the present invention tried to discover new materials and methods for manufacturing them, and completed the present invention by producing and utilizing a Yoshino cherry tree bioconversion extract through a bioconversion method.
본 발명은 생물전환법을 통해 얻은 왕벚나무 생물전환 추출물을 유효성분으로 포함하는 항염용 조성물을 제공하는 것을 목적으로 한다.An object of the present invention is to provide an anti-inflammatory composition comprising a Yoshino cherry tree bioconversion extract obtained through a bioconversion method as an active ingredient.
본 발명의 일 구체예에 따른 항염용 조성물은 왕벚나무 생물전환 추출물을 유효성분으로 포함하는 것일 수 있다.The anti-inflammatory composition according to an embodiment of the present invention may include a Yoshino cherry tree bioconversion extract as an active ingredient.
상기 왕벚나무(Prunus yedoensis Matsum)는 우리나라 남부 지방과 제주도 한라산에 자생하며, 현재 전국적으로 흔히 서식한다. 생물전환법을 통해 왕벚나무로부터 추출물을 얻기 위해서는 왕벚나무의 뿌리, 줄기, 잎, 열매, 꽃 등을 제한 없이 사용할 수 있다. 바람직하게는, 왕벚나무 꽃일 수 있다. 이때, 왕벚나무를 직접 이용하거나, 또는 왕벚나무로부터 추출된 추출물을 이용할 수 있다. 왕벚나무 추출물은 당업계에 알려진 추출 방법을 제한 없이 사용하여 얻을 수 있다. 추출 방법의 일례로는 냉침 추출, 초음파 추출, 환류 냉각 추출, 열수 추출, 가압 추출, 용매 추출 등을 들 수 있다. 추출시 용매를 사용할 경우에는 당업계에 알려진 추출 용매를 제한 없이 사용할 수 있다. 추출 용매의 일례로는 정제수, 메탄올, 에탄올, 프로판올, n-부탄올, 이소-부탄올, 아세트산, 디메틸 포마미드(dimethyl formamide), 디메틸 설폭사이드(dimethyl sulfoxide, DMSO), 아세톤, 아세토나이트릴, 에틸 아세테이트, 메틸 아세테이트, 펜탄, 헥산, 클로로포름, 디에틸 에테르, 사염화탄소, 테트라하이드로퓨란(tetrahydrofuran, THF) 등을 들 수 있다. 예를 들면, 왕벚나무 뿌리, 줄기, 잎, 열매, 꽃 등을 실온에서 건조하여 추출 탱크에 투입한 후 정제수를 첨가하여 80 내지 140℃의 온도, 1 내지 2 atm의 기압으로 추출하여 얻은 왕벚나무 추출물을 얻을 수 있다.The Yoshino cherry tree ( Prunus yedoensis Matsum) is native to the southern regions of Korea and Hallasan, Jeju Island, and is now commonly inhabited nationwide. In order to obtain an extract from a Yoshino cherry tree through a bioconversion method, roots, stems, leaves, fruits, and flowers of the Yoshino cherry tree can be used without limitation. Preferably, it may be a Yoshino cherry tree flower. In this case, the Yoshino cherry tree may be used directly, or an extract extracted from the Yoshino cherry tree may be used. Yoshino cherry tree extract can be obtained by using an extraction method known in the art without limitation. Examples of the extraction method include cold immersion extraction, ultrasonic extraction, reflux cooling extraction, hot water extraction, pressure extraction, and solvent extraction. When using a solvent for extraction, an extraction solvent known in the art may be used without limitation. Examples of the extraction solvent are purified water, methanol, ethanol, propanol, n-butanol, iso-butanol, acetic acid, dimethyl formamide, dimethyl sulfoxide (DMSO), acetone, acetonitrile, ethyl acetate , Methyl acetate, pentane, hexane, chloroform, diethyl ether, carbon tetrachloride, tetrahydrofuran (THF), and the like. For example, Yoshino cherry tree roots, stems, leaves, fruits, flowers, etc. were dried at room temperature and put into an extraction tank, then purified water was added to extract them at a temperature of 80 to 140°C, and at 1 to 2 atm air pressure. An extract can be obtained.
본 발명에서 사용되는 용어 "생물전환" 또는 "생물전환법"은 미생물을 이용하여 기질 또는 전구물질로부터 인산화(phosphorylation), 글리코실화(glycosylation) 등의 구조적 변화를 유도한 화합물을 생산, 제조하는 방법을 의미한다. 상기 인산화는 인산화효소(kinase)의 작용에 의하여 인산기(phosphoric acid group, HOPO(OH)O-)가 기질의 수소 원자와 치환됨으로써 기질에 결합하는 것을 의미하며, 상기 글리코실화는 기질에 단당체, 다당체 등의 당류(glucoside)가 첨가되는 것을 의미한다. 상기 생물전환은 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) 균주에 의한 것일 수 있다.The term "bioconversion" or "bioconversion method" used in the present invention is a method of producing and manufacturing a compound inducing structural changes such as phosphorylation and glycosylation from a substrate or precursor using microorganisms. Means The phosphorylation means that a phosphoric acid group (HOPO(OH)O-) is substituted with a hydrogen atom of a substrate by the action of a phosphatase (kinase) to bind to the substrate, and the glycosylation is a monosaccharide to the substrate, It means that sugars such as polysaccharides are added. The bioconversion may be by Bacillus amyloliquefaciens strain.
상기 왕벚나무 생물전환 추출물은 왕벚나무 또는 왕벚나무로부터 추출된 추출물 (왕벚나무 추출물)을 균주와 함께 배양함으로써 생물전환에 의해 왕벚나무에 존재하는 유효성분의 함량이 증가할 수 있고, 왕벚나무에 함유된 유용한 화합물들의 작용기가 치환되어 기존에 존재하지 않던 신규 화합물의 생성을 유도할 수 있다. 이러한 왕벚나무 생물전환 추출물은 바실러스 아밀로리퀘파시엔스 균주에 의해 생물전환된 것일 수 있으며, 바실러스 아밀로리퀘파시엔스 균주에 의한 생물전환을 통해 왕벚나무로부터 추출된 왕벚나무 생물전환 추출물은 염증 반응에 의한 산화질소(nitric dxide; NO), 프로스타글란딘(prostaglandin E2; PGE2), 염증전 사이토카인(pro-inflammatory cytokine) 생성을 저해하는 활성을 가질 수 있다. 구체적으로는, LPS에 의해 유도된 염증 반응에서 산화질소, 프로스타글란딘, 염증전 사이토카인의 생성 관련 mRNA, 단백질의 발현을 저해할 수 있다.The bio-converted extract of Yoshino cherry can increase the content of the active ingredient present in the Yoshino cherry tree by bio-conversion by culturing the Yoshino cherry or the extract extracted from the Yoshino cherry (Yellow cherry extract) together with the strain, and contained in the Yoshino cherry tree. The functional groups of the useful compounds can be substituted, leading to the production of new compounds that did not exist. The Yoshino cherry tree bioconversion extract may be bioconverted by the Bacillus amyloliquefaciens strain, and the Yoshino cherry bioconversion extract extracted from the Yoshino cherry tree through the bioconversion by the Bacillus amyloliquefaciens strain may cause an inflammatory reaction. Nitric dxide (NO), prostaglandin E2 (PGE2), may have activity that inhibits the production of pro-inflammatory cytokines. Specifically, in the inflammatory response induced by LPS, it is possible to inhibit the expression of mRNA, protein related to the production of nitric oxide, prostaglandin, and pre-inflammatory cytokines.
본 발명에서 사용되는 용어 "항염용 조성물"은 염증을 예방하거나, 발생된 염증을 없애는 작용을 하는 조성물을 의미한다. 이러한 조성물은 식품 조성물, 화장료 조성물, 약학 조성물 등으로 이용될 수 있다.The term "composition for anti-inflammatory" as used in the present invention means a composition that prevents inflammation or acts to eliminate the inflammation. Such a composition may be used as a food composition, cosmetic composition, pharmaceutical composition, and the like.
상기 식품 조성물은 식품 첨가제 또는 기능성 식품에 적합한 모든 제형으로 제공될 수 있으며, 일례로 용액, 유탁액, 점성형 혼합물, 분말, 과립, 정제, 캡슐 등일 수 있다. 이때, 본 발명이 목적으로 하는 주 효과를 손상시키지 않는 범위 내에서 제형의 제제화에 필요하고 적절한 각종 기제 및/또는 첨가물을 포함할 수 있으며, 그 효과를 떨어뜨리지 않는 범위 내에서 향료, 색소, 살균제, 산화방지제, 방부제, 보습제, 점증제, 무기염류, 유화제 등의 첨가제를 더 포함할 수 있다. 이러한 첨가제들의 배합량은 제형 또는 사용 목적에 따라 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 선택될 수 있다. 예를 들면, 식품 조성물의 전체 중량을 기준으로, 첨가제 0.01 ~ 5 중량%, 보다 구체적으로는 0.1 ~ 3 중량%일 수 있다.The food composition may be provided in any formulation suitable for food additives or functional food, and may be, for example, solutions, emulsions, viscous mixtures, powders, granules, tablets, capsules, and the like. At this time, the present invention may include various bases and/or additives necessary and appropriate for the formulation of the formulation within a range that does not impair the main effect of the object, fragrances, pigments, fungicides within a range that does not impair the effect , Antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and the like may further contain additives. The blending amount of these additives may be selected within a range that does not impair the purpose and effect of the present invention depending on the formulation or purpose of use. For example, based on the total weight of the food composition, the additive may be 0.01 to 5% by weight, more specifically 0.1 to 3% by weight.
상기 화장료 조성물은 국소 적용에 적합한 모든 제형으로 제공될 수 있으며, 일례로 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 스프레이 등일 수 있다. 이때, 본 발명이 목적으로 하는 주 효과를 손상시키지 않는 범위 내에서 제형의 제제화에 필요하고 적절한 각종 기제 및/또는 첨가물을 포함할 수 있으며, 그 효과를 떨어뜨리지 않는 범위 내에서 비이온 계면활성제, 실리콘 폴리머, 체질안료, 향료, 방부제, 살균제, 산화 안정화제, 유기 용매, 이온성 또는 비이온성 증점제, 유연화제, 산화방지제, 자유라디칼 파괴제, 불투명화제, 안정화제, 에몰리언트(emollient), 실리콘, α-히드록시산, 소포제, 보습제, 비타민, 곤충 기피제, 향료, 보존제, 계면활성제, 소염제, 물질 P 길항제, 충전제, 중합체, 추진제, 염기성화 또는 산성화제, 착색제 등의 첨가제를 더 포함할 수 있다. 이러한 첨가제들의 배합량은 제형 또는 사용 목적에 따라 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 선택될 수 있다. 예를 들면, 화장료 조성물의 전체 중량을 기준으로, 첨가제 0.01 ~ 5 중량%, 보다 구체적으로는 0.1 ~ 3 중량%일 수 있다.The cosmetic composition may be provided in any formulation suitable for topical application, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsions It may be a foundation, a wax foundation, a spray, or the like. At this time, the present invention may include various bases and/or additives necessary and appropriate for the formulation of the formulation within a range that does not impair the main effect desired, a nonionic surfactant within a range that does not impair the effect, Silicone polymers, extenders, fragrances, preservatives, fungicides, oxidation stabilizers, organic solvents, ionic or nonionic thickeners, softeners, antioxidants, free radical disruptors, opacifiers, stabilizers, emollients, silicones, α-hydroxy acids, anti-foaming agents, moisturizing agents, vitamins, insect repellents, flavoring agents, preservatives, surfactants, anti-inflammatory agents, substance P antagonists, fillers, polymers, propellants, basic or acidifying agents, coloring agents may further include additives, etc. . The blending amount of these additives may be selected within a range that does not impair the purpose and effect of the present invention depending on the formulation or purpose of use. For example, based on the total weight of the cosmetic composition, the additive may be 0.01 to 5% by weight, more specifically 0.1 to 3% by weight.
상기 약학 조성물은 의약품에 적합한 모든 제형으로 제공될 수 있으며, 일례로 고체, 반고체 또는 액상 형태의 경구 투여제 또는 비경구 투여제일 수 있다. 경구 투여를 위한 제제는 정제, 환제, 과립제, 캡슐제, 산제, 세립제, 분제, 유탁제, 시럽제, 펠렛제 등일 수 있다. 비경구 투여 위한 제제는 주사제, 점적제, 연고, 로션, 스프레이, 현탁제, 유제, 좌제 등일 수 있다. 이때, 본 발명이 목적으로 하는 주 효과를 손상시키지 않는 범위 내에서 제형의 제제화에 필요하고 적절한 각종 기제 및/또는 첨가물을 포함할 수 있으며, 그 효과를 떨어뜨리지 않는 범위 내에서 담체, 계면활성제, 부형제, 착색료, 향신료, 보존료, 안정제, 완충제, 현탁제 등의 첨가제를 더 포함할 수 있다. 이러한 약학 조성물은 경구, 비경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내, 피하 등으로 투여될 수 있다. 약학 조성물의 유효성분은 투여 받을 대상의 연령, 성별, 체중, 병리 상태 및 그 심각도, 투여 경로 또는 처방자의 판단에 따라 달라질 수 있다. 예를 들면, 1일 투여 용량은 0.01 mg/kg/일 내지 100 mg/kg/일, 보다 구체적으로는 0.1 mg/kg/일 내지 50 mg/kg/일일 수 있다.The pharmaceutical composition may be provided in any formulation suitable for pharmaceuticals, and may be, for example, an oral dosage form or a parenteral dosage form in a solid, semi-solid or liquid form. Formulations for oral administration may be tablets, pills, granules, capsules, powders, granules, powders, emulsions, syrups, pellets, and the like. Formulations for parenteral administration may be injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. At this time, the present invention may include various bases and/or additives necessary and appropriate for the formulation of the formulation within a range that does not impair the main effect of the object, and carriers, surfactants, within a range that does not impair the effect, Additives such as excipients, colorants, spices, preservatives, stabilizers, buffers, suspending agents may be further included. Such pharmaceutical compositions may be administered orally, parenterally, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous, and the like. The active ingredient of the pharmaceutical composition may vary depending on the age, gender, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. For example, the daily dose may be from 0.01 mg/kg/day to 100 mg/kg/day, more specifically from 0.1 mg/kg/day to 50 mg/kg/day.
본 발명에 따른 왕벚나무 생물전환 추출물은 생물전환법을 통해 왕벚나무로부터 추출된 것으로, 염증 반응에 의한 산화질소, 프로스타글란딘, 염증전 사이토카인의 생성을 저해함으로써 항염 조성물로 유용하게 활용될 수 있다.The Yoshino cherry tree bioconversion extract according to the present invention is extracted from the Yoshino cherry tree through a bioconversion method, and can be usefully used as an anti-inflammatory composition by inhibiting the production of nitric oxide, prostaglandin, and pre-inflammatory cytokines by an inflammatory reaction.
도 1은 본 발명의 일 실시예에 따른 생물전환법을 통해 왕벚나무 꽃 추출물(PY)로부터 추출된 왕벚나무 생물전환 추출물(BR)의 HPLC 분석 결과이다.
도 2는 본 발명의 일 실시예에 따라 LPS로 자극된 RAW 264.7 세포에 대한 PY 및 PYBR의 세포 생존능 결과이다.
도 3은 본 발명의 일 실시예에 따라 LPS로 자극된 RAW 264.7 세포에 대한 PY 및 PYBR의 (a) NO 생성, (b) COX-2 및 iNOS 단백질 발현 저해 결과이다.
도 4는 본 발명의 일 실시예에 따라 LPS로 자극된 RAW 264.7 세포에 대한 PYBR의 PEG2, IL-1β, IL-6 생성 저해 결과이다. 1 is an HPLC analysis result of a Yoshino cherry bioconversion extract (BR) extracted from a Yoshino cherry flower extract (PY) through a bioconversion method according to an embodiment of the present invention.
Figure 2 is a cell viability results of PY and PYBR for RAW 264.7 cells stimulated with LPS according to an embodiment of the present invention.
3 is a result of (a) NO production, (b) COX-2 and iNOS protein expression inhibition of PY and PYBR for RAPS 264.7 cells stimulated with LPS according to an embodiment of the present invention.
Figure 4 is a result of inhibiting the production of PEG2, IL-1β, IL-6 of PYBR for RAPS 264.7 cells stimulated with LPS according to an embodiment of the present invention.
이하, 첨부된 도면을 참조하며 본 발명을 보다 상세하게 설명한다. 그러나, 이러한 설명은 본 발명의 이해를 돕기 위하여 예시적으로 제시된 것일 뿐, 본 발명의 범위가 이러한 예시적인 설명에 의하여 제한되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the accompanying drawings. However, these descriptions have been presented by way of example only to help understanding of the present invention, and the scope of the present invention is not limited by these exemplary descriptions.
실시예 1. 왕벚나무 생물전환 추출물 및 세포 준비Example 1. Yoshino cherry tree bioconversion extract and cell preparation
1-1. 왕벚나무 꽃 추출물의 제조1-1. Preparation of Yoshino Cherry Flower Extract
왕벚나무 꽃을 제주자원식물연구소로부터 입수하였고, 부착물을 제거한 후 깨끗한 담수로 씻어 실온에서 완전히 건조시켰다. 추출탱크에 건조된 왕벚나무 꽃을 투입하고, 70% 에탄올 1L를 첨가하였다. 실온에서 24시간 동안 추출하여 1차 추출물을 회수하고, 추출탱크에 70% 에탄올 1 L를 추가로 첨가하였다. 실온에서 24시간 동안 추출하여 2차 추출물을 회수하였다. 회수한 1차 추출물과 2차 추출물을 혼합하여 5.0㎛의 공극 크기를 갖는 필터(TOYO, Japan)로 여과하여 왕벚나무 꽃 추출물을 수득하였다. 여과된 추출물을 5 브릭스(brix) 이상으로 진공농축하여 준비하였다.The Yoshino cherry tree flowers were obtained from the Jeju Institute of Plant Resources, and after removing the deposits, they were washed with clean fresh water and dried completely at room temperature. Dried cherry flowers were added to the extraction tank, and 1 L of 70% ethanol was added. The extract was recovered at room temperature for 24 hours to recover the primary extract, and 1 L of 70% ethanol was additionally added to the extraction tank. Secondary extract was recovered by extracting at room temperature for 24 hours. The recovered primary extract and secondary extract were mixed and filtered through a filter (TOYO, Japan) having a pore size of 5.0 μm to obtain a Yoshino cherry tree flower extract. The filtered extract was prepared by vacuum concentration to 5 brix or more.
1-2. 생물전환법1-2. Bioconversion method
생물전환에 사용된 미생물은 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) KCTC 43033 균주로, 미생물자원센터(Korean Collection for Type Culture, KCTC)에서 분양 받았다.The microorganisms used for bioconversion were Bacillus amyloliquefaciens KCTC 43033 strains, which were purchased from the Korean Collection for Type Culture (KCTC).
KCTC 43033 균주를 영양 액체배지(Nutrient broth) (쇠고기 추출물 3.0 g/L, 펩톤 5.0 g/L 함유) 1 L에서 30℃의 온도로 20시간 동안 배양하였다. 배양 후, 5,000 rpm에서 10분 동안 원심분리하여 미생물 펠렛(pellet)을 수득하였다.KCTC 43033 strain was incubated for 20 hours at a temperature of 30 °C at 1 L of nutrient liquid medium (containing 3.0 g/L of beef extract and 5.0 g/L of peptone). After incubation, microbial pellets were obtained by centrifugation at 5,000 rpm for 10 minutes.
수득된 미생물 펠렛을 PG 버퍼 (50 mM 포스페이트 pH 7.2 및 2% 글리세롤 함유)로 세척하고, PG 버퍼 5 mL에 현탁시켰다. 이후 현탁액에 기질 (왕벚나무 꽃 추출물)을 첨가하여 30℃에서 72시간 동안 배양하였다.The obtained microbial pellet was washed with PG buffer (containing 50 mM phosphate pH 7.2 and 2% glycerol) and suspended in 5 mL of PG buffer. Subsequently, a substrate (Yoshino cherry tree flower extract) was added to the suspension and incubated at 30°C for 72 hours.
배양이 끝난 후 배양액을 원심분리하여 상등액을 수거하고, 감압농축하여 H20에 용해시켜 시료 (왕벚나무 생물전환 추출물)를 준비하였다.After the culture was completed, the culture solution was centrifuged to collect the supernatant, concentrated under reduced pressure, and dissolved in
1-3. HPLC 분석1-3. HPLC analysis
1-2.에서 준비된 시료에 대해 HPLC(high performance liquid chromatography, 고성능 액체 크로마토그래피) 분석을 통해 생물전환 화합물의 생성여부를 확인하였다. The sample prepared in 1-2. was confirmed whether or not a bioconversion compound was generated through HPLC (high performance liquid chromatography) analysis.
구체적으로, Prominence HPLC System (Shimadzu, Japan) 장치를 사용하였다. 검출기로 LC-2030/2040 PDA Detector를, 칼럼으로 Shim-pack GIS를 사용하였다. 용매로 0.1% TFA water와 아세토나이트릴(acetonitrile)을 사용하였으며, 분석 조건은 30분까지 아세토나이트릴 10%에서 100%로 하였다. 파장을 254 nm로, 유속을 1 mL/min으로 설정하였고, 주입량을 10 ㎕으로 하였다.Specifically, a Prominence HPLC System (Shimadzu, Japan) apparatus was used. LC-2030/2040 PDA Detector was used as the detector, and Shim-pack GIS was used as the column. As a solvent, 0.1% TFA water and acetonitrile were used, and the analysis conditions were from 10% to 100% acetonitrile until 30 minutes. The wavelength was set to 254 nm, the flow rate was set to 1 mL/min, and the injection amount was set to 10 μl.
그 결과, 도 1에 나타낸 바와 같이, 왕벚나무 생물전환 추출물(BR)은 왕벚나무 꽃 추출물(PY)에 존재하지 않는 다수의 피크(peak)를 포함하며, 일부 피크의 세기가 강해진 것으로 확인되었다.As a result, as shown in FIG. 1, the Yoshino cherry bioconversion extract (BR) includes a number of peaks that are not present in the Yoshino cherry flower extract (PY), and it has been confirmed that the intensity of some peaks is enhanced.
1-4. 시료 및 세포 배양1-4. Sample and cell culture
시료는 왕벚나무 꽃 추출물(PY) 및 1-2.에서 분리된 왕벚나무 생물전환 추출물(PYBR)이 50, 100, 200 μM의 농도로 사용되었다.As a sample, a Yoshino cherry flower extract (PY) and a Yoshino cherry bioconversion extract (PYBR) isolated from 1-2. were used at concentrations of 50, 100, and 200 μM.
RAW 264.7 세포는 100 units/mL 페니실린-스트렙토마이신(penicillin-streptomycin)과 10% FBS(fetal bovine serum)가 함유된 DMEM (Dulbecco's Modified Eagle Medium, Gibco, Grand Island, NY, USA) 배지를 사용하여 5% CO2 배양기(incubator)에서 37℃로 배양되었다. 세포를 2일 간격으로 계대배양하였다.RAW 264.7 cells were prepared using DMEM (Dulbecco's Modified Eagle Medium, Gibco, Grand Island, NY, USA) medium containing 100 units/mL penicillin-streptomycin (10%) and 10% fetal bovine serum (FBS). It was incubated at 37 °C in a% CO 2 incubator. Cells were passaged every 2 days.
실험예 1. 세포 생존능(cell viability) 확인Experimental Example 1. Confirmation of cell viability
RAW 264.7 세포는 10% FBS가 함유된 DMEM 배지를 사용하여 8.0 Х 104 cells/mL로 24웰-마이크로플레이트에 분주되어 18시간 동안 배양되었다. 이후, 세포에 PY 또는 PYBR과 LPS (1 μg/mL)를 동시 처리하여 24시간 동안 배양한 후 MTT 시약 (Thiazolyl Blue Tetrazolium Blue)을 처리하여 4시간 동안 반응시켰다. 반응 후 세포 배양액을 제거하고 남은 펠렛에 DMSO 첨가한 후 570 nm에서 흡광도를 측정하였다.RAW 264.7 cells were cultured in a 24-well-microplate at 8.0 Х 10 4 cells/mL using DMEM medium containing 10% FBS and cultured for 18 hours. Thereafter, the cells were incubated for 24 hours by simultaneously treating PY or PYBR with LPS (1 μg/mL), followed by reaction with MTT reagent (Thiazolyl Blue Tetrazolium Blue) for 4 hours. After the reaction, the cell culture was removed and DMSO was added to the remaining pellet, and absorbance was measured at 570 nm.
그 결과, 도 2에 나타낸 바와 같이, PYBR은 처리 농도에 따라 세포 생존능을 변화시키지 않으며, PY에 비해 세포 생존능이 우수한 것으로 확인되었다.As a result, as shown in Figure 2, PYBR does not change the cell viability according to the treatment concentration, it was confirmed that the cell viability is superior to PY.
실험예 2. NO 저해 활성 확인Experimental Example 2. Confirmation of NO inhibitory activity
2-1. NO 생성2-1. NO generation
RAW 264.7 세포는 10% FBS가 함유된 DMEM 배지를 사용하여 8.0 Х 104 cells/mL로 24웰-마이크로플레이트에 분주되어 18시간 동안 배양되었다. 이후, 세포에 PY 또는 PYBR과 LPS (1 μg/mL)를 동시 처리하여 24시간 동안 배양하였다. 생성된 NO는 그리스(Griess) 시약을 이용하여 세포 배양액 중에 존재하는 NO2-의 형태로 측정되었다. 세포 배양액 100 μL와 그리스 시약을 동량 혼합하여 10 분 동안 실온암소에서 반응시킨 후 ELISA 측정기(reader)를 이용하여 540 nm에서 흡광도를 측정하였다. RAW 264.7 cells were cultured in a 24-well-microplate at 8.0 Х 10 4 cells/mL using DMEM medium containing 10% FBS and cultured for 18 hours. Subsequently, the cells were incubated with PY or PYBR and LPS (1 μg/mL) for 24 hours. The generated NO was measured in the form of NO 2 − present in the cell culture using a Grease reagent. 100 μL of the cell culture solution and the same amount of the grease reagent were mixed and reacted at room temperature for 10 minutes, and then absorbance was measured at 540 nm using an ELISA reader.
그 결과, 도 3의 a에 나타낸 바와 같이, PYBR은 PY와 유사하게 처리 농도에 따라 NO 생성을 저해하는 것으로 확인되었다.As a result, as shown in FIG. 3A, PYBR was confirmed to inhibit NO production according to the treatment concentration similar to PY.
2-2. COX-2 및 iNOS의 단백질 발현2-2. Protein expression of COX-2 and iNOS
RAW 264.7 세포는 10% FBS가 함유된 DMEM 배지를 사용하여 1.0 Х 105 cells/mL로 6웰-마이크로플레이트에 분주되어 18시간 동안 배양되었다. 이후, 세포에 PYBR과 LPS (1 μg/mL)를 동시 처리하여 24시간 동안 배양하였다. 세포를 세포용해 버퍼(lysis buffer)로 1시간 동안 용해시킨 후 원심분리하여 단백질 함유 상등액을 분리하였다. 상등액 내 단백질 농도를 BSA kit (Bio-Rad, USA)로 정량하였다. 정량된 단백질을 8 ~ 12%의 폴리아크릴아미드 겔(polyacrylamide gel)에 전기영동하여 PVDF 막(poly-vinylidene difluoride membrane) (Milipore, USA)에 200 mA로 2시간 동안 전이(transfer)시킨 후 막을 블로킹(blocking)하였다. 이후, 막을 1차 항체인 항-COX-2 항체 (Anti-COX-2 (Rabbit) Antibody, RK100-401-226, Rockland Immunochemicals, Inc., USA), 항-iNOS 항체 (Rabbit Anti iNOS, BRAHP2399, BIO-RAD, USA)와 4℃에서 24시간 반응시키고, 2차 항체 (HRP Anti-Rabbit IgG (H&L), RK611-103-122, Rockland Immunochemicals, Inc., USA; Anti-mouse IgG (H&L), RK610-103-121, Rockland Immunochemicals, Inc., USA)를 1:5,000 또는 1:10,000으로 희석하여 상온에서 1시간 반응시켰다. 단백질 밴드를 ECL kit (Bio-Rad, USA)를 사용하여 영상 농도측정기(imaging densitometer)에서 확인하였다.RAW 264.7 cells were cultured for 18 hours by dispensing in a 6-well microplate at 1.0 Х 10 5 cells/mL using DMEM medium containing 10% FBS. Subsequently, the cells were incubated for 24 hours by simultaneously treating PYBR and LPS (1 μg/mL). Cells were lysed with a lysis buffer for 1 hour and centrifuged to separate the protein-containing supernatant. Protein concentration in the supernatant was quantified with a BSA kit (Bio-Rad, USA). The quantified protein was electrophoresed on an 8-12% polyacrylamide gel, transferred to a PVDF membrane (poly-vinylidene difluoride membrane) (Milipore, USA) at 200 mA for 2 hours, and then the membrane was blocked. (blocking). Subsequently, the primary antibody to be blocked is an anti-COX-2 antibody (Anti-COX-2 (Rabbit) Antibody, RK100-401-226, Rockland Immunochemicals, Inc., USA), an anti-iNOS antibody (Rabbit Anti iNOS, BRAHP2399, BIO-RAD, USA) for 24 hours at 4° C., secondary antibody (HRP Anti-Rabbit IgG (H&L), RK611-103-122, Rockland Immunochemicals, Inc., USA; Anti-mouse IgG (H&L), RK610-103-121, Rockland Immunochemicals, Inc., USA) was diluted 1:5,000 or 1:10,000 and reacted at room temperature for 1 hour. Protein bands were confirmed on an imaging densitometer using an ECL kit (Bio-Rad, USA).
그 결과, 도 3의 b에 나타낸 바와 같이, PYBR은 iNOS 및 COX-2의 단백질 발현을 저해하는 것으로 확인되었다.As a result, as shown in FIG. 3B, PYBR was confirmed to inhibit protein expression of iNOS and COX-2.
실험예 3. PGE2 및 염증전 사이토카인 저해 활성 확인Experimental Example 3. Confirmation of PGE2 and pre-inflammatory cytokine inhibitory activity
RAW 264.7 세포는 10% FBS가 함유된 DMEM 배지를 사용하여 8.0 Х 104 cells/mL로 24웰-마이크로플레이트에 분주되어 18시간 동안 배양되었다. 이후, 세포에 PYBR과 LPS (1 μg/mL)를 동시 처리하여 24시간 동안 배양한 후 세포 배양액을 원심분리 (12,000 rpm, 3 분)하여 얻어진 상층액 내 PGE2 및 염증전 사이토카인의 함량을 측정하였다. 모든 측정 시료를 정량 전까지 냉동보관 (-20℃ 하였다. PGE2는 PGE2 ELISA Kit (MousePGE2, R&DSystems, MN, USA)로, 염증전 사이토카인은 Mouse IL-6 ELISA Kit (San diego, California, USA), Mouse IL-1β/IL-1F2 (R&D Systems, MN, USA)로 측정되었다. RAW 264.7 cells were cultured in a 24-well-microplate at 8.0 Х 10 4 cells/mL using DMEM medium containing 10% FBS and cultured for 18 hours. Subsequently, PYBR and LPS (1 μg/mL) were simultaneously treated to the cells, followed by incubation for 24 hours, followed by centrifugation of the cell culture (12,000 rpm, 3 minutes) to measure the content of PGE2 and pre-inflammatory cytokines in the supernatant obtained. Did. All measurement samples were stored frozen until quantification (-20°C. PGE2 is a PGE2 ELISA Kit (MousePGE2, R&DSystems, MN, USA). Pre-inflammatory cytokines are Mouse IL-6 ELISA Kit (San diego, California, USA), Mouse IL-1β/IL-1F2 (R&D Systems, MN, USA).
그 결과, 도 4에 나타낸 바와 같이, PYBR은 처리 농도에 따라 PGE2, IL-1β, IL-6의 생성을 저해하는 것으로 확인되었다.As a result, as shown in FIG. 4, PYBR was confirmed to inhibit the production of PGE2, IL-1β, and IL-6 depending on the treatment concentration.
종합적으로, 생물전환법을 통해 추출된 왕벚나무 생물전환 추출물은 우수한 항염 활성을 갖는다는 것을 알 수 있었다.Overall, it was found that the Yoshino cherry bioconversion extract extracted through the bioconversion method has excellent anti-inflammatory activity.
Claims (8)
상기 생물전환은 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) 균주에 의한 것이며,
상기 조성물은 염증 반응에 의한 산화질소(NO), 프로스타글란딘(PGE2), 염증전 사이토카인(pro-inflammatory cytokine)의 생성을 저해하는 활성을 갖는 것인, 조성물.
As an anti-inflammatory composition comprising a Yoshino cherry tree bioconversion extract as an active ingredient,
The bioconversion is by Bacillus amyloliquefaciens strain,
The composition has an activity of inhibiting the production of nitrogen oxide (NO), prostaglandin (PGE2), pro-inflammatory cytokine (pro-inflammatory cytokine) by the inflammatory reaction, the composition.
상기 왕벚나무는 뿌리, 줄기, 잎, 열매 및 꽃으로 이루어진 군에서 선택되는 하나 이상인 것인 조성물.
The method according to claim 1,
The Yoshino cherry tree is one or more compositions selected from the group consisting of roots, stems, leaves, fruits and flowers.
상기 조성물은 식품 조성물, 화장료 조성물 및 약학 조성물로 이루어진 군에서 선택되는 하나 이상인 것인 조성물.
The method according to claim 1,
The composition is at least one selected from the group consisting of food compositions, cosmetic compositions and pharmaceutical compositions.
상기 식품 조성물은 용액, 유탁액, 점성형 혼합물, 분말, 과립, 정제 및 캡슐로 이루어진 군에서 선택되는 하나 이상의 제형인 것인 조성물.
The method according to claim 5,
The food composition is one or more formulations selected from the group consisting of solutions, emulsions, viscous mixtures, powders, granules, tablets and capsules.
상기 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이로 이루어진 군에서 선택되는 하나 이상의 제형인 것인 조성물.
The method according to claim 5,
The cosmetic composition is at least one selected from the group consisting of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations and sprays A composition that is a formulation.
상기 약학 조성물은 고체, 반고체 또는 액상 형태의 경구 투여제 또는 비경구 투여제인 것인 조성물.
The method according to claim 5,
The pharmaceutical composition is a solid, semi-solid or liquid form of the oral administration or parenteral administration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190121316A KR102127282B1 (en) | 2019-10-01 | 2019-10-01 | Composition for Anti-inflammatory Comprising Biorenovation Extract of Prunus yedoensis Matsum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190121316A KR102127282B1 (en) | 2019-10-01 | 2019-10-01 | Composition for Anti-inflammatory Comprising Biorenovation Extract of Prunus yedoensis Matsum |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102127282B1 true KR102127282B1 (en) | 2020-06-29 |
Family
ID=71400778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190121316A KR102127282B1 (en) | 2019-10-01 | 2019-10-01 | Composition for Anti-inflammatory Comprising Biorenovation Extract of Prunus yedoensis Matsum |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102127282B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102317282B1 (en) * | 2021-04-30 | 2021-10-26 | 주식회사 바람인터내셔날 | Cosmetic Composition for Skin Barrier Enhancement and Skin Anti-inflammation Comprising Dahlia Pinnata Fermented Extract |
KR20220095488A (en) * | 2020-12-30 | 2022-07-07 | 주식회사 헬리오스 | A whitening composition and its manufacturing method by bio-renovation of Rape flower Extract |
KR102542032B1 (en) | 2022-12-26 | 2023-06-13 | 주식회사 코씨드바이오팜 | Cosmetic Composition for Skin Improvement with Prunus yedoensis Extract as Active Ingredient |
KR20240073365A (en) | 2022-11-18 | 2024-05-27 | 국립낙동강생물자원관 | Composition for improving inflammation or endotoxemia comprising cherry tree extract as an active ingredient |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130032625A (en) * | 2011-09-23 | 2013-04-02 | 주식회사 장원 | Complex composition comprising fermented tea |
KR101628939B1 (en) | 2015-12-14 | 2016-06-09 | 백진주 | Cosmetic composition for improving atopic dermatitis and dry skin containing the botanical extracts prepared by bioconversion |
-
2019
- 2019-10-01 KR KR1020190121316A patent/KR102127282B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130032625A (en) * | 2011-09-23 | 2013-04-02 | 주식회사 장원 | Complex composition comprising fermented tea |
KR101628939B1 (en) | 2015-12-14 | 2016-06-09 | 백진주 | Cosmetic composition for improving atopic dermatitis and dry skin containing the botanical extracts prepared by bioconversion |
Non-Patent Citations (3)
Title |
---|
International journal of cosmetic science, 2014, 36(6), pp. 527-530 * |
Journal of medicinal food, 2014, 17(4), pp, 407-413 * |
KSBB Journal, 2019, 34(1), pp. 49-53 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220095488A (en) * | 2020-12-30 | 2022-07-07 | 주식회사 헬리오스 | A whitening composition and its manufacturing method by bio-renovation of Rape flower Extract |
KR102509273B1 (en) | 2020-12-30 | 2023-03-14 | 주식회사 헬리오스 | A whitening composition and its manufacturing method by bio-renovation of Rape flower Extract |
KR102317282B1 (en) * | 2021-04-30 | 2021-10-26 | 주식회사 바람인터내셔날 | Cosmetic Composition for Skin Barrier Enhancement and Skin Anti-inflammation Comprising Dahlia Pinnata Fermented Extract |
KR20220149395A (en) * | 2021-04-30 | 2022-11-08 | 주식회사 바람인터내셔날 | Cosmetic Composition for Skin Barrier Enhancement and Skin Anti-inflammation Comprising Dahlia Pinnata Fermented Extract |
KR102623887B1 (en) | 2021-04-30 | 2024-01-12 | 주식회사 바람인터내셔날 | Cosmetic Composition for Skin Barrier Enhancement and Skin Anti-inflammation Comprising Dahlia Pinnata Fermented Extract |
KR20240073365A (en) | 2022-11-18 | 2024-05-27 | 국립낙동강생물자원관 | Composition for improving inflammation or endotoxemia comprising cherry tree extract as an active ingredient |
KR102542032B1 (en) | 2022-12-26 | 2023-06-13 | 주식회사 코씨드바이오팜 | Cosmetic Composition for Skin Improvement with Prunus yedoensis Extract as Active Ingredient |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102127282B1 (en) | Composition for Anti-inflammatory Comprising Biorenovation Extract of Prunus yedoensis Matsum | |
KR20110132629A (en) | Method for preparing a centella asiatica extract rich in madecassoside and in terminoloside | |
JP2023528104A (en) | Peelstone oligosaccharide, Peelstone oligosaccharide derivative, preparation method and application thereof | |
Liu et al. | An in vivo and in vitro assessment of the anti-inflammatory, antinociceptive, and immunomodulatory activities of Clematis terniflora DC. extract, participation of aurantiamide acetate | |
KR101404398B1 (en) | Anti-wrinkle cosmetic composition | |
JP7407269B2 (en) | Skin topical compositions with enhanced anti-eczema efficacy | |
KR20090043115A (en) | Ecklonia cava-derived phlorotannin-containing composition for treating or preventing atopic disease | |
KR102558753B1 (en) | Cosmetic composition comprising fermented extraction of houttuynia cordata | |
WO2019098808A2 (en) | Composition for improving skin damage caused by microdust comprising culture or extract of aureobasidium pullulans strain | |
KR101367306B1 (en) | Whitening or moisturizing cosmetic composition comprising tetradecanol extracted from dendropanax morbifera lev | |
Zeng et al. | Immune regulation and inflammation inhibition of Arctium lappa L. polysaccharides by TLR4/NF-κB signaling pathway in cells | |
EP3197460B1 (en) | Dermocosmetic or pharmaceutical use of a composition containing at least one inhibitor of certain chemokines | |
EP3501529B1 (en) | Method for preparing an extract of chrysanthemum morifolium with an effect of treating skin diseases, extract of chrysanthemum morifolium with an effect of treating skin diseases and pharmaceutical composition containing the extract | |
KR102086854B1 (en) | Anti-oxidant or anti-inflammatory cosmetic compositions containing the plants extract of Cyperaceae | |
CN107118089B (en) | Method for preparing paeonol from plant and application of paeonol in preparation of cosmetics | |
KR102259832B1 (en) | Formononetin 7-O-phosphate and Composition for Anti-inflammatory Comprising the Same | |
CN108660175B (en) | A kind of plant source polypeptide and the application in cosmetics | |
KR102076180B1 (en) | Cosmetic Composition For Alleviating or Preventing Hair Loss Comprising Extract of Triticum Vulgare Bran | |
KR20200069616A (en) | Anti-inflammatory composition comprising Prunus pendula for. ascendens (Makino) Ohwi | |
US8012486B2 (en) | Composition for treating atopic dermatitis comprising hirsutenone as an active ingredient | |
TWI618540B (en) | Composition for preventing renal toxicity caused by drug toxicity, preparation method thereof and Its use | |
JP2012140405A (en) | Production method of beomycesic acid-rich thamnolia vermicularis extract | |
KR20160057196A (en) | the composition of whitening cosmetic formula containing Pachymic acid | |
KR20130045631A (en) | Composition for improving immunological disease comprising syringaresinol | |
KR20190088758A (en) | Anti-atopic composition comprising extract of Geomgangsong thinning by-product as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant |